In approximately 99% of patients, the initial prasugrel LD and MD were 20 and 3.75 mg, respectively; 95.1% of patients received an initial LD. Prasugrel was administered as described in the package insert , and aspirin was used concomitantly in most patients. Nearly 70% of prasugrel treatment completions or discontinuations occurred as patients switched to other anti-platelet agents. Because prasugrel was only allowed to be prescribed for a period of 2 weeks during the first year after its launch, these patients were prescribed other anti-platelet agents for subsequent long-term treatment.